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950Objective:Our aim was to test whether a unidirectional valve patch would provide benefit to early and long-term
survival for patients with ventricular septal defect and severe pulmonary artery hypertension.
Methods: Eight hundred seventy-six cases of ventricular septal defect with severe pulmonary artery hypertension
were closed with or without a unidirectional valve patch and were classified as the unidirectional valve patch
(UVP) group (n ¼ 195) and nonvalve patch (NVP) group (n¼ 681), respectively. Propensity scores of inclusion
into the UVP group were used to match 138 pairs between the 2 groups. Kaplan–Meier survival curves were con-
structed to compare early and long-term survival.
Results: For the 138 propensity-matched pairs, there were 7 and 9 early deaths (in-hospital deaths) in the UVP
and NVP groups, respectively. The difference in early mortality between the 2 groups did not reach statistical
significance (c2¼ 0.265, P ¼ .6064). With a mean of 9.2 4.92 years’ and 2511 patient-years’ follow-up, there
were 6 late deaths in the UVP group and 7 late deaths in the NVP group. The difference in actuarial survival at 5,
10, 15, and 18 years between the 2 groups was not significant (log-rank test, c2¼ 0.565, P¼ .331). The difference
in the late mortality between the groups with or without a patent patch at the time of discharge did not reach sta-
tistical significance (c2¼ 1.140, P¼ .2856). There was no difference between the 2 groups in the 6-minute walk
distance assessed at the last follow-up (525.9  88.0 meters for the UVP group and 536.5  95.8 meters for the
NVP group, F ¼ 1.550, P ¼ .214).
Conclusion: A unidirectional valve patch provides no benefits to early and long-term survival when it is used to
deal with ventricular septal defect and severe pulmonary artery hypertension. (J Thorac Cardiovasc Surg
2010;139:950-5)Severe pulmonary artery hypertension (PAH) could put
patients with a large ventricular septal defect (VSD) at
increased risk of morbidity and mortality when closure of
the VSD is performed. Facing this situation, in some cardiac
centers a unidirectional valve patch (UVP) has been used to
deal with severe PAH associated with a large VSD, especially
in the population affected by Eisenmenger syndrome, in an
attempt to provide better early and long-term survival. To
test whether a UVP for closure of a VSD benefits patients
with severe PAH, we retrospectively reviewed our practice
in patients who underwent the UVP procedure to close a large
VSD. The present workwas to compare the early and late out-
comes of surgical closure of a large VSD with severe PAH
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The Journal of Thoracic and Cardiovascular Surgformed to match the 2 distinct groups and permit comparison
and to study the association of UVP and mortality.MATERIALS AND METHODS
The institutional review board approved this study and waived the
requirement for individual consent because of its retrospective nature.
Patients
From January 1, 1990, to November 1, 2008, 1012 patients with a VSD
with severe PAH were admitted to and treated in Anzhen Hospital. For 876
(86.56%) of these patients, complete preoperative homodynamic data were
available. The medical records of all 876 patients were retrospectively re-
viewed, and the patients were retrospectively divided into the UVP group
(n ¼ 195) or the nonvalve patch (NVP) group (n ¼ 681), respectively, ac-
cording to whether a UVP was used during surgical closure of the VSD.
PAH is defined as a mean pulmonary artery pressure (mPAP) of greater
than 25mmHg at rest or 30 mmHgwith exercise, and severe PAH is further
defined as an mPAP of greater than 50 mmHg (at rest), which is in line with
the definition used by the American College of Chest Physicians.1 Pulmo-
nary artery pressure (PAP) and mPAP and cardiac output were measured
through a right heart catheterization. All patients were subjected to a 10-min-
ute inhalation of pure oxygen and a 10-minute inhalation of 30 ppm of nitric
oxide (NO), respectively, during right heart catheterization. A decrease in
pulmonary vascular resistance (PVR) of greater than 6.5 Wood’s units
(WU) from baseline was considered a positive reaction for pure oxygen or
NO challenge. If a patient had a bidirectional shunt on echocardiographic
analysis and a total PVR of greater than 10 WU, a pulmonary vascular resis-
tance index (PVRI) of greater than 6 WU/m2, a pulmonary/systemic flowery c April 2010
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CBP ¼ cardiopulmonary bypass
mPAP ¼ mean pulmonary artery pressure
NO ¼ nitric oxide
NVP ¼ nonvalve patch
NYHA ¼ New York Heart Association
PAH ¼ pulmonary artery hypertension
PAP ¼ pulmonary artery pressure
PVR ¼ pulmonary vascular resistance
PVRI ¼ pulmonary vascular resistance index
Qp/Qs ¼ pulmonary/systemic flow ratio
6MWD ¼ 6-minute walk distance
sPAP ¼ systolic pulmonary artery pressure
UVP ¼ unidirectional valve patch
WU ¼ Wood’s unitsC
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Dratio (Qp/Qs) of less than 1.5, or a hemoglobin value of greater than 160 g/L,
he or she would be more likely assigned to the UVP group. The age at which
the patients were admitted to Anzhen Hospital ranged from 2 to 37 years.
The preoperative demographics and risk factors of patients from the 2
groups are presented in Table 1. Patients in the UVP group were older
and statistically more likely to have a history of cyanosis on exertion
(P ¼ .0001), refractory right heart failure (P ¼ .0003), a hemoglobin value
of 160 g/L or greater (P¼ .001), a bidirectional shunt on echocardiographic
analysis (P ¼ 0.0001), a systolic pulmonary artery pressure (sPAP) of 110
mmHg or greater (P¼ .007), a pulmonary/systemic systolic artery pressure
ratio of 0.9 or greater (P ¼ .0324), higher PVR (P ¼ .019), higher PVRI
(P ¼ .015), higher mPAP (P ¼ 0.040), lower Qp/Qs (P ¼ .0001), lower
PaO2 (P ¼ .0009), lower arterial oxygen saturation (P ¼ .017), shorter
6-minute walk distance (6MWD; P ¼ .0003), or less chance of a positive
reaction to NO (P ¼ .0112) or pure oxygen (P ¼ .0001) inhalation during
the right heart catheterization than were the patients in the NVP group.
Therapeutic Regimen
Before the procedure, a Swan–Ganz pulmonary artery catheter was in-
serted for all patients, and PAP was monitored throughout the perioperative
period. All patients underwent operations with general anesthesia and mod-
erate hypothermic cardiopulmonary bypass (CPB) with cardiac arrest. After
the CPBwas established through cannulation in the superior and inferior ve-
nae cavae and ascending aorta, the ascending aorta was clamped, and crys-
talloid cardioplegia was perfused. The VSD was closed by means of
a standard procedure with a Dacron patch in the NVP group, whereas
a UVP was used to close the VSD in the UVP group, as previously de-
scribed.2 In brief, the UVP was constructed from a Dacron patch approxi-
mately as large as the defect to be closed. A hole approximately 0.5 to
1.0 cm in diameter was made in the patch somewhat off center. A piece
of quadrangular pericardium was attached by sutures to the surface of the
Dacron patch. The 3 edges of pericardium were continuously sutured, and
1 edge was left unattached. This unattached edge of pericardium should pro-
vide a small opening not to exceed 0.5 cm, and appropriate tension should
be maintained on the pericardial edge so that the valve mechanism will not
be loose and incompetent. The CPB duration was 95.2 24.3 minutes, and
the clamping time was 34.4  18.3 minutes. The nasopharyngeal tempera-
ture during CPB was 28.5C 5.5C. During the follow-up period, 48% of
the cohort were treated with a b-blocker, 78% were treated with an angio-
tensin-converting enzyme inhibitor, 59%were treated with a calcium chan-
nel blocker (diltiazem), 42% were treated with a cardiotonic glycoside,
38% were treated with a diuretic, and 19% were treated with potassium-
sparing diuretics, such as spironolactone or amiloride. Six percent of pa-The Journal of Thoracic and Catients were anticoagulated with warfarin, whereas 23% of patients were
treated with antiarrhythmic drugs. In addition, 25% of patients had oxygen
therapy at home, and 3% of patients were treated with advanced therapies
for PAH using bosentan (a dual endothelin receptor antagonist), sildenafil
(a phosphodiesterase-5 inhibitor), or a combination of both.
Follow-up
Of the 876 patients, valid and complete follow-up information was ob-
tained from 843 (96.2%) through mail, e-mail, telephone calls, or outpatient
department visits. Long-term clinical outcome was retrospectively assessed
up toNovember2008 through telephone interviewsof thepatientsusinga stan-
dard questionnaire and by reviewing themedical records of their cardiologists,
general practitioners, or both when appropriate. All patients were asked to re-
turn to AnzhenHospital or a local hospital for an echocardiogram and clinical
evaluation. During the follow-up period, PAPwasmeasured through echocar-
diographic analysis, and the 6MWDwas also assessed. Baseline demograph-
ics, procedural data, and perioperative outcomes were recorded. The mean
follow-up period for the whole cohort was 102.2 61.6 months.
Statistical Analysis
All statistical analyses were performed retrospectively with SAS for
Windows version 8.2 (SAS Institute, Inc, Cary, NC). Continuous variables
are presented as means  standard deviations and were analyzed with Stu-
dent’s t test. Categorical data are presented as total numbers and relative fre-
quencies. Comparisons between the 2 groups were made by using the
Mann–Whitney U test or the c2 test, as appropriate. Kaplan–Meier survival
curves were constructed to illustrate the actuarial survival. Comparisons of
time-related data are made by using the log-rank test. In an attempt to con-
trol for selection bias, propensity scores were estimated by using uncondi-
tional logistic regression to determine the predicted probability of inclusion
into the UVP group for each of the 876 patients.
First, multivariate logistic regression was used to identify the characteris-
tics with which surgical closure of a VSD with a UVP was liable to be
selected. Of 27 defining baseline variables, 8 were not significant in the logis-
tic regression analysis. These were sex, left ventricular ejection fraction, car-
diac/thoracic ratio, electrocardiographic rhythm,NewYorkHeart Association
(NYHA) functional class, cyanosis at rest, hemoptysis, and clubbing of fin-
gers and toes. Logistic regression analysis identified 10 variables as significant
predictors of UVP use. These 10 variables were a PAP of greater than 110mm
Hg, a PVR of greater than 10WU, a PVRI of greater than 6WU/m2, a Qp/Qs
of less than 1.5, a hemoglobin value of greater than 160 g/L, a negative reac-
tion to NO and pure oxygen inhalation in the right heart catheterization (de-
fined as a PVR decrease >6.5 WU after inhalation of NO and pure
oxygen), bidirectional shunt on ultracardiographic analysis, a systolic heart
murmur of less than grade III out of 6 grades, and an arterial oxygen saturation
of less than 92% on air.
Second, a propensity score was calculated for all 876 patients using these
significant regression coefficients. Each patient in the UVP group was then
closely matched with an NVP group patient having the same or nearest pro-
pensity score (with the same propensity score  0.05, the approach is to
match UVP and NVP subjects on the first 5 digits of the propensity score).
The matching program was performed in the total population and has suc-
cessfully matched 138 patients in the UVP group with 138 patients in the
NVP group. The resulting 138 pairs of matched patients are the focus of
the outcome analysis in this study.RESULTS
Entire Unmatched Patient Population
During the in-hospital stay, there were 11 (5.64%) and 41
(6.02%) early deaths in the UVP and NVP groups, respec-
tively. Of the 52 early deaths, 47 were due to PAH crisis
and acute right heart failure, 3 were due to reperfusion injury,rdiovascular Surgery c Volume 139, Number 4 951
TABLE 1. Preoperative baseline demographic variables and risk factors in the UVP and NVP groups
Demographics and preoperative risk factors UVP group (n ¼ 195) NVP group (n ¼ 681) P value (c2)
Age (y) 25.76  8.51 18.40  8.13 .028 (5.96)
Female sex (%) 35.90 40.96 .202 (1.627)
Right heart failure (%) 18.46 12.04 .0003 (13.359)
Cyanosis at rest (%) 5.64 4.70 .591 (0.288)
Cyanosis on exertion (%) 40.00 27.17 .0006 (11.885)
Hemoglobin 160 g/L (%) 34.87 22.91 .001 (10.838)
Clubbing of fingers and toes (%) 24.10 18.65 .092 (2.832)
Systolic heart murmur II/6 grade (%) 65.94 78.26 .0225 (5.206)
6MWD<400 m (%) 27.69 16.15 .0003 (13.266)
LVEF 0.55  0.07 0.61  0.06 .082 (2.223)
Bidirectional shunt on UCG (%) 73.39 46.98 .0001 (43.890)
PVR (WU) 15.9  6.31 12.06  6.42 .019 (5.87)
PVRI (WU/m2) 10.6  4.21 8.40  4.48 .015 (6.32)
QP/Qs<1.5 (%) 46.67 27.31 .0001 (26.261)
sPAP 110 mm Hg (%) 49.23 38.47 .007 (7.260)
sPAP/sBP ratio 0.90 0.97  0.18 0.87  0.145 .0324 (4.974)
mPAP (mm Hg) 81.48  17.21 69.73  15.2 .040 (3.87)
SaO2 0.82  0.15 0.93  0.05 .017 (6.890)
PaO2<60 mm Hg (%) 22.56 12.92 .0009 (11.012)
Hematoasthenia pulmonary field on x-ray film (%) 26.67 18.94 .0188 (5.516)
CTR 0.63  0.064 0.62  0.069 .323 (0.977)
Sinus rhythm on ECG (%) 94.36 95.74 .415 (0.665)
RBBB (%) 35.89 27.90 .0311 (4.645)
Hemoptysis (%) 4.62 3.38 .417 (0.660)
NYHA functional class III (%) 18.46 17.77 .824 (0.05)
Positive reaction to NO inhalation (%) 39.49 49.78 .0112 (6.440)
Positive reaction to pure oxygen inhalation (%) 43.59 61.23 .0001 (19.288)
UVP, Unidirectional valve patch; NVP, nonvalve patch; 6MWD, 6-minute walk distance; LVEF, left ventricular ejection fraction; UCG, ultracardiography; PVR, pulmonary vas-
cular resistance;WU, Wood’s units; PVRI, pulmonary vascular resistance index; Qp/Qs, pulmonary/systemic flow ratio; sPAP, systolic pulmonary artery pressure; sPAP/sBP, pul-
monary/systemic systolic artery pressure ratio; mPAP, mean pulmonary artery pressure; SaO2, arterial oxygen saturation; CTR, cardiac/thoracic ratio; ECG, echocardiography;
RBBB, right bundle branch block; NYHA, New York Heart Association; NO, nitric oxide.
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difference in the early mortality between the UVP and NVP
groups did not reach statistical significance (c2 ¼ 0.001,
P ¼ .973). With a mean of 102.2  61.6 months and 7969
patient-years’ follow-up, there were 10 late deaths in the
UVP group and 26 late deaths in the NVP group. Of the total
36 cases of late death, 27 were due to refractory chronic right
heart failure, 3 were due to PAH crisis, 4 were due to copious
hemoptysis, and 2 were due to severe lung infection.
Propensity-Matched Pairs (n ¼ 138)
All characteristics that differed significantly between the 2
groups before matching became comparable (Table 2). Dur-
ing the in-hospital stay, there were 7 (5.07%) and 9 (6.52%)
early deaths for the UVP and NVP groups, respectively. Of
the 16 early deaths, 14 were due to PAH crisis, and 2 were
due to reperfusion injury. According to the c2 test, the differ-
ence in the early mortality between the UVP and NVP
groups did not reach statistical significance (c2 ¼ 0.265,
P ¼ .6064). Intraoperative epicardial or transesophageal
echocardiographic analysis showed the UVP open and blood
flowing from the right to the left ventricle in all of the UVP
group patients. The UVP gradually closed with improve-952 The Journal of Thoracic and Cardiovascular Surgment of hemodynamics in the UVP group, as evidenced
with serial echocardiographic analysis, and thus by the third
postoperative day, the UVP had closed in 118 patients and
remained only slightly open in 20 patients. At 72 hours after
the VSD closure procedure, the mPAP assessed with
a Swan–Ganz pulmonary artery catheter was 49.7  29.6
mm Hg for the UVP group and 52.2  28.1 mm Hg for
the NVP group (t ¼ 0.7196, P ¼ .4724).
With a mean of 9.2  4.92 years’ and 2511 patient-years’
follow-up, there were 6 late deaths in the UVP group and 7
late deaths in the NVP group. Among the 13 total cases of
late death, 10 were due to refractory chronic right heart fail-
ure, 1 was due to PAH crisis, and 1 was due to copious
hemoptysis. As shown in Figure 1 and Table 3, the
Kaplan–Meier survival curves were estimated to compare
the long-term actuarial survival between the 2 groups in the
138 propensity score-matched pairs. The actuarial survival
at 5, 10, 15, and 18 years of the 2 groups was not significantly
difference (log-rank test, c2 ¼ 0.565, P ¼ .331). During the
follow-up period, of the 20 patients known to have a patent
patch at the time of discharge, there were 2 late deaths,
whereas of the 240 patients (including 129 in the NVP group
and 111 in the UVP group known to have a closed patch at theery c April 2010
TABLE 2. Preoperative baseline demographic variables and risk factors of the propensity-matched patients
Demographics and preoperative risk factors UVP group (n ¼ 138) NVP group (n ¼ 138) P value (c2)
Age (yr) 25.43  9.32 24.42  8.76 .082 (4.76)
Female sex (%) 32.60 31.88 .898 (0.017)
Right heart failure (%) 15.22 14.49 .866 (0.029)
Cyanosis at rest (%) 15.9 13.8 .612 (0.258)
Cyanosis on exertion (%) 38.41 32.60 .314 (1.013)
Hemoglobin 160 g/L (%) 28.99 25.36 .499 (0.458)
Clubbing of fingers and toes (%) 23.91 19.57 .381 (0.767)
Systolic heart murmur II/6 grade (%) 72.46 78.26 .264 (1.249)
6MWD<400 m (%) 23.19 21.01 .689 (0.163)
LVEF 0.55  0.07 0.60  0.07 .082 (2.223)
Bidirectional shunt on UCG (%) 72.46 65.94 .241 (1.377)
PVR (WU) 13.4  4.54 12.72  4.67 .319 (1.87)
PVRI (WU/m2) 8.65  4.07 8.48  3.51 .332 (1.65)
QP/Qs<1.5 (%) 52.17 44.93 .228 (1.450)
sPAP 110 mm Hg (%) 50 46.38 .547 (0.363)
sPAP/sBP 0.97  0.18 0.96  0.165 .624 (0.874)
mPAP (mm Hg) 76.48  17.21 75.81  16.4 .19 (1.87)
SaO2 0.82  0.15 0.85  0.05 .270 (1.045)
PaO2<60 mm Hg (%) 21.74 19.57 .656 (0.199)
Hematoasthenia lung field on x-ray film (%) 27.54 22.46 .331 (0.947)
CTR 0.63  0.064 0.62  0.069 .323 (0.977)
Sinus rhythm on ECG (%) 93.48 96.38 .274 (1.04)
RBBB (%) 35.51 34.06 .801 (0.064)
Hemoptysis (%) 4.38 2.90 .520 (0.415)
NYHA functional class III (%) 19.57 15.94 .431 (0.620)
Positive reaction to NO inhalation (%) 49.28 57.97 .148 (2.098)
Positive reaction to pure oxygen inhalation (%) 50.72 60.87 .090 (2.879)
See Table 1 for a list of abbreviations.
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Dtime of discharge), there were 11 late deaths. The difference in
the late mortality between the groups with and without a pat-
ent patch at the time of discharge did not reach statistical
significance (c2 ¼ 1.140, P ¼ .2856). Echocardiographic
analysis at follow-up showed that the UVP had closed in
121 of the 125 survivors in the UVP group, whereas the other
4 had a 1- to 3-mm shunt across the UVP. Echocardiographic
analysis found severe tricuspid regurgitation in 9 UVP group
patients and in 11 NVP group patients (c2 ¼ 0.274, P ¼
.6008). The sPAP assessed through echocardiographic analy-
sis was 56.7  21.1 mm Hg for the UVP group and 58.2 
19.3 mm Hg for the NVP group (t ¼ 0.4625, P ¼ .6441).
The 6MWDs assessed at the last follow-up were 525.9 
88.0 meters for the UVP group and 536.5  95.8 meters
for the NVP group, according to the t test, and the difference
between the 2 groups did not reach statistical significance (t¼
0.9060, P ¼ .3658). Of the 125 survivors in the UVP group,
there were 8 in NYHA functional class III to IV, and of the
122 survivors in the NVP group, there were 9 in NYHA func-
tional class III to IV (c2 ¼ 0.7617, P ¼ .092).
DISCUSSION
The closure of a VSD is usually performed at an early age
and before the onset of increased PVR in most industrialized
countries. Although patients with a large VSD and increasedThe Journal of Thoracic and CaPVR are rarely seen in surgically advanced countries, they
continue to represent a significant proportion of the congen-
ital heart disease population in underdeveloped countries.
Delayed presentation and operations for patients with VSD
and PAH are not uncommon in the developing world.3,4
The closure of VSD in patients with a PVR of 10 WU or
greater is considered to be contraindicated because of high
operative mortality and debatable long-term results.5 These
patients often have a turbulent postoperative course as the re-
sult of PAH. A large VSD exposes the patients to the risk of
PAH and tends to worsen with age. The course of the disease
is variable and depends on the size of the defect, the magni-
tude of the left-to-right shunt, and the pulmonary vascular
response to increased pulmonary flow and pressure.6
Pulmonary hypertensive crisis can be associated with
acute congestive heart failure, which is the main cause of
death.7-10 To prevent acute right ventricular failure from re-
fractory PAH and early postoperative death, a wide variety
of UVPs have been described.11 The UVP technique pro-
vides a simple physiologic mechanism for unloading the
right ventricle during periods of severe, acute, and transient
or sustained PAH. In 1959, Bailey and colleagues first ap-
plied flap valves made of a compressed ring of polyvinyl
sponge in 8 patients with atrial and ventricular septal shunts.
The conventional closure procedure appeared to be too riskyrdiovascular Surgery c Volume 139, Number 4 953
FIGURE 1. The Kaplan–Meier survival curve for the unidirectional valve
patch (UVP) and nonvalve patch (NVP) groups (survival years).
TABLE 3. The actuarial survival of the UVP and NVP groups for the
138 propensity-matched pairs (%)
UVP group NVP group P value* (c2)
5-y Survival 94.0  2.1 93.5  2.1 .565 (0.331)
10-y Survival 93.0  2.3 90.5  2.9
15-y Survival 88.8  3.6 85.6  4.4
18-y Survival 62.4  18.6 67.9  10.0
UVP, Unidirectional valve patch; NVP, nonvalve patch. *Log-rank test of Kaplan–
Meier survival curve between the UVP and NVP groups.
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Seven of the 8 patients with Bailey’s device survived. There
was a gradual decrease in PAP and eventually total or near
total closure of the defect.12,13 The UVP was also described
by Ad and associates,14 who adopted a 1-way, valved, atrial
septal patch in 18 patients. Then Zhou and coworkers15
adopted a similar UVP in the treatment of VSD complicated
with Eisenmenger syndrome, and Zhang and colleagues16
developed a unidirectional monovalve homologous aortic
patch for repair of VSD with PAH. Novick and associates17
reported the use of a nonfenestrated patch closure for chil-
dren younger than 6 years with severe PAH, but the opera-
tive mortality was very high. In recent years, creation of
an intracardiac shunt to prevent right ventricular failure
has been used with success.18
Although the fabrication method of these UVPs was not
exactly the same, the rationale for them was practically iden-
tical, which permits a right-to-left shunt to relieve right heart
overload and left heart hypovolemia and helps the patient
survive the PAH crisis. Kannan and coworkers19 reported
that the closure of a large VSD in patients with increased
PVR was warranted, and the early mortality rate in their
studies using a nonfenestrated patch was 13.1%. Novick
and associates17 reported a study in a series of 91 children
with a large VSD and increased PVR who underwent dou-
ble-patch VSD closure with an early mortality of 3.6%. Al-
though this mortality rate is much lower than that seen in
Kannan and coworkers’ study,19 this comparison was not
warranted because the children in the Kannan and co-
workers’ study were older (7.5 years) than those in Novick
and associates’ study17 (4.0 years), and the patients’ PVRs
in the 2 studies were not comparable. We believe that this
difference could not provide evidence to support the hypoth-
esis that the double-flap valve VSD closure technique pro-
duces a lower mortality rate among patients with PAH and
increased PVR.
The purpose of surgical repair of the congenital systemic-
to-pulmonary shunts with severe PAH is to achieve a higher954 The Journal of Thoracic and Cardiovascular Surgsurvival rate with excellent quality of life.20 It would not be
considered beneficial when the patients only obtain opera-
tional success but not a higher long-term survival rate with
excellent quality of life. The debate about the adoption of
the UVP is whether the UVP would provide benefits to early
and long-term survival for the closure of systemic-to-pulmo-
nary shunts with severe PAH. It is difficult to reach a conclu-
sion from the results with various techniques because of the
small numbers in the existing studies and the heterogeneity
of the patient population and because of the absence of a ran-
domized study with control subjects or a series with litera-
ture controls at the point of the hierarchy of evidence.
From our analysis, of the 138 propensity-matched pairs,
there were no significant differences in the in-hospital mor-
tality or actuarial survival at 5, 10, 15, and 18 years and in
6MWDs at the last follow-up between the 2 groups. To in-
vestigate whether a patent patch at the time of discharge
would provide further benefits for long-term survival, we
compared the long-term survival of the patients known to
have a fenestrated patch with that of those who do not
have a fenestrated patch or have a closed patch at the time
of discharge. Again, the difference in the late mortality be-
tween the groups with and without a patent patch at the
time of discharge did not reach statistical significance.
Thus we conclude that the UVP provides no benefits to early
and long-term survival when it is used to repair a VSD with
severe PAH.
This study is a retrospective analysis, and therefore some
confounding factors might be involved to show any clear re-
lationship between the early and late prognosis and the use
of the UVP in the closure of a VSD with severe PAH. De-
spite the relatively large number of VSD and UVP cases
in our study compared with previously published reports
and the propensity score analysis used in the present work,
which allowed us to balance the 2 nonequivalent groups
and reduce significant bias for subclassification of the pa-
tients, a prospective randomized study is needed to provide
more substantial evidence for our conclusion.
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